Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eramkafusp alfa - Assertio Therapeutics

Next Previous
Drug Profile

Eramkafusp alfa - Assertio Therapeutics

Alternative Names: Anti-CD20 monoclonal antibody+IFN; IGN-002

Latest Information Update: 12 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunGene
  • Developer ImmunGene; The Leukemia & Lymphoma Society; Valor Biotherapeutics
  • Class Antineoplastics; Immunotherapies; Interferons; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Interferon-alpha replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 23 Feb 2022 Spectrum Pharmaceuticals terminates a phase-I trial due to strategic reasons in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (NCT02519270)
  • 23 Feb 2022 Valor Biotherapeutics withdrew a phase II extension trial prior to enrolment due to strategic reasons in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (NCT02847949)
  • 05 Jan 2022 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top